But directly elicited or implicitly accepted willingness to pay for ecosystem services requires consumers to have improbable understanding of processes: willingness to pay for final products, services or disservices delivered to the consumer is a more appropriate basis.
Depending on the parameter altered, the ICER ranges from greater than the accepted willingness to pay (WTP) threshold of £30,000 per QALY to dominant (clinically superior and cost saving).
The resulting incremental cost per QALY falls below commonly accepted willingness to pay thresholds.
An ICER of €30,000 per LYG was assumed as a generally accepted willingness to pay threshold in Germany [ 41].
Second-generation telecare did not appear to be a cost-effective addition to usual care, assuming a commonly accepted willingness to pay for QALYs.
The ICUR was not favorable to infliximab based on the existing evidence, according to commonly accepted willingness to pay threshold (e.g., US $50,000).
This number is the ICER, and we note that it falls below commonly accepted willingness to pay thresholds (which range between £20,000 and £30,000 per QALY in the UK 35).
This implies that already after one year, ICERs are well below the commonly accepted willingness-to-pay threshold of €30,000 £25,000000) determining cost-effectiveness.
If taking into account the commonly, albeit not officially, accepted willingness-to-pay threshold of €30,000 for a QALY in the health care sector in Spain, 35 bazedoxifene is a cost-effective option.
Sensitivity analysis, however, suggests that these assumptions do not change our conclusion that domestic B-notification follow-up is cost-effective under widely accepted willingness-to-pay standards (e.g. $50 000 per QALY gained).
We present an experiment designed to study the psychological basis for the willingness to accept (WTA)–willingness to pay (WTP) gap.
